KR20040014757A - Composition comprising the extract of Cistanche deserticola Y.C.MA showing enhancing activity of the neurite outgrowth and neurotrophic effects - Google Patents

Abstract

PURPOSE: Provided are an extract of Cistanche deserticola Y.C.MA showing enhancing activity of neurite outgrowth and neurotrophic effects and a composition containing the same. The composition is effective for protection of nerve cells and prevention and treatment of degenerative brain diseases. CONSTITUTION: A crude extract of Cistanche deserticola Y.C.MA has nerve growth factor like activities, such as increase of the growth of nerve, inhibition of nerve cell apoptosis and regeneration of damaged nerve cells. A composition for protection of nerve cells and prevention and treatment of degenerative diseases comprises the crude extract and its polar or non-polar solvent extract, wherein the polar solvent includes water, methanol, butanol or their mixture and the non-polar solvent includes hexane, chloroform, and ethylacetate.

Description

Composition for the extract of Cistanche deserticola Y.C.MA showing enhancing activity of the neurite outgrowth and neurotrophic effects}

The present invention relates to a sarcoma extract having a nerve growth factor-like action for the treatment and prevention of degenerative brain diseases.

In the twentieth century, the rapid development of life sciences and medicine has led to an increase in the average life expectancy of humans and a growing proportion of the elderly population, leading to new social problems, especially senile neurological diseases such as stroke and Alzheimer's disease. , AD), and Parkinson's disease (PD) have been shown to be fatal neurological dysfunctions.

Growth, differentiation and cell death of neurons in the nervous system are important regulatory processes in normal development and intrinsic function of tissues and in maintaining homeostasis, respectively. There are two forms of neuronal cell death: apoptosis and necrosis. Necrotic necrosis is caused by damage leading to rapid imbalances of intracellular ions, swelling of the cytoplasm and mitochondria, and nuclear membranes after lysis of the cytoplasm. It is induced by the destruction of, which refers to acute death in which cells die due to sudden injury such as ischemic, hypothermia, stroke, physical or chemical trauma (Tomei et al . ; Proc. Natl. Acad. Sci. USA ., 90 , pp853-857, 1993), unaffected by protein synthesis inhibitors and a representative example of what occurs in the nervous system when neurons are damaged by activation of ionic glutamic acid receptors. Apoptosis, also known as scheduled cell death, is characterized by membrane changes such as cell shrinkage, membrane blebbing, disruption of the cytoskeleton, and nuclear changes such as chromatin condensation. (Kerr JF, J. Pathol., 107 (3), pp 217-219, 1972: Arends MJ & Morris RG, Am. J. Pathol., 136 (3), pp 593-608, 1990). With the loss of mitochondrial function, cells form an apoptotic body, a small structure surrounded by a membrane, which is phagocytosis completely removed by neighboring cells or macrophages in an animal model. It is removed from the tissue without an inflammatory response due to the outflow of the cellular contents.

In multicellular organisms, all actions such as cell growth, differentiation and migration are regulated by regulatory factors that exist outside the cell. Neurons also need these regulatory factors, which are neuro-regulatory factors, which are proteins that are released from target cells and affect the growth differentiation survival of neurons in the Central Nervous System (CNS) and the Peripheral Nervous System (PNS). All are called nerve growth factors. There are five related factors: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurofactor NT-3 (Neurotrophin-3), NT-4, NT-5 These neurons are each synthesized, differentiated, expressed, and expressed at different target sites, but the amino acid sequence constituting each is very similar between species. Nerve factors suppress neuronal cell death in the nervous system. Neuronal cell death occurs when a neuronal factor is deficient, and is a form of cell death that relies mostly on cell death related genes. It is well known that neuronal factors inhibit neuronal cell death during neuronal development.

Among these neuronal factors, nerve growth factor (NGF) was isolated by Levi-Montalcini from snake venom or mouse sarcoma in the early 1950's. It has been reported that the growth of axons is several times accelerated (Levi-Montalcini R., Birth Defects Orig Artic Ser, 19 (4), pp3-22, 1983). In the past, nerve growth factors were thought to promote neuronal division, but now known to prevent neuronal degeneration by inhibiting neuronal degeneration. These receptors are present in the dorsal root ganglion, brain, and sympathetic dominant organs. In vivo, sympathetic dominant organs, such as the heart, biosynthesize nerve growth factors, which are absorbed at the nerve endings and transported in the axon direction. Reaching neuronal cells has been reported to promote protein synthesis here (Mahalik TJ, Investig Dermatol Symp Proc., Aug; 2 (1), pp 14-18, 1997).

In the central nervous system, there are many reports that NGF protects against neuronal damage. For example, cutting of the Fimbria-fornix (Cholinergic axon cutting, Choliergic axotomy) is a It prevents cholinergic addition from cholinergic neurons to the hippocampus, which causes the cholinergic neurons to gradually degenerate. When the nerve growth factor is added after cutting, the degeneration of cholinergic neurons is almost completely suppressed. BDNF) has a similar effect to nerve growth factor on cholinergic ablation (Hefti FJ, Neurosci, Aug; 6 (8), pp2155-2162, 1986). In addition, the relationship between nerve growth factors and peripheral nerves, the role of nerve growth factors in mature animals has not yet been clearly identified, but recent reports show that the injection of antibodies of nerve growth factors causes sympathetic ganglion destruction and norepinephrine The activity of synthesizing tyrosine hydroxylase and dopamine beta-hydroxylase is also reported to be reduced (Levi-Montalcinin et al . ; Bull. Soc. Sci. Med Grand Duche Luxemb, 115 (2), pp69-74). , 1978). On the other hand, the injection of nerve growth factors from the outside increases the survival of NGF-sensitive nerves and increases the degree of nerve dominance in the tissues, and reports that externally injected nerve growth factors weaken the developmental changes after peripheral nerve injury (Zettler). C, Head RJ, Rush RA, Brain Res., 538 (2), pp251-262, 1991), suggest that neuronal growth factor may play an important role in neuronal regeneration after nerve injury. These results show that the organization's nerve growth factor and sympathetic control are closely related.

About 50% of neurons in development during the normal development of the nervous system are eliminated by apoptosis (Barres BA, Schmid R, Sendnter M, Raff MC., Development, 118 (1), pp283-95, 1993), and target cells. The neuronal factors secreted by are known to determine the survival of neurons. Growth factors, such as nerve growth factors, are essential for neurons to survive, grow, and differentiate in their normal state. However, these nerve growth factors do not cross the BBB (Blood brain barrier) in the brain because of their molecular weight. Therefore, it is difficult to see the therapeutic effect in degenerative brain diseases. Therefore, the synthesis of endogenous nerve growth factors should be further induced, and further development of materials that play the same role as nerve growth factors is urgently needed.

As a perennial parasitic herbaceous plant ( Cistanche deserticola YCMA) used in the present invention is a perennial parasitic herb that grows on alkaline lands, dry springs, limbs, and It is a herbal medicine that has been commonly used in the sense of nourishing tonic, since it moisturizes and moisturizes and moisturizes crude oil. Contains enzymes, fats and trace amounts of alkaloids and crystalline neutrals (Bo Bo-seop and Shin Min-kyo); Chinese medicine metabolism, Yeonglimsa, pp 888 ~ 889, 1998), Cistanoside, Cistanoside F in Japan , Tubuloside A, tubuloside B, 2'-acetylacetoside, echinacoside, 3'-α-rhamnopyranoside, isoacetheside (isoacteoside), acetoside, and syringalide A components were isolated.

Pharmacological actions include blood pressure lowering, bowel movements, tonic action, and saliva secretion and respiratory paralysis. Recent studies have reported antioxidant and anti-aging effects. The efficacy of the effects is not known at all.

In the present invention, the effects of growth differentiation of neurons for sarcoma are examined through various biochemical experiments, and the role of growth factors that are important for inhibiting cell death, which is the biggest cause of degenerative brain disease, is derived from crude sarcoma extract and nonpolar solvent soluble extract. In order to determine whether or not to induce the neural growth factor and whether or not to induce neural growth factor was carried out through the molecular biology experiments and microscopic observation through cell line culture.

As a result, the present invention was completed by confirming that the crude extract for breeding and the nonpolar solvent soluble extract according to the present invention have neuronal cell protective activity by inhibiting neuronal cell death and increasing the synthesis of neuronal factors.

Disclosure of Invention It is an object of the present invention to provide a pharmaceutical composition and a dietary supplement containing a sarcoma extract, a polar solvent and a non-polar solvent soluble extract that are effective in protecting neurons and preventing and treating degenerative brain diseases.

Figure 1a is a diagram showing the growth of nerve axons of PC12 cell line when treated with only the culture medium as a control, Figure 1b is a diagram showing the growth of nerve axons of PC12 cell line when treated with 10μg / ml crude sarcoma extract,

Figure 2a is a diagram showing the axon length of the nerve axons after treatment with only the culture medium as a control, Figure 2b is a neuron factor (NGF) 2ng / ㎖, Figure 2c is NGF 10ng / ㎖, Figure 2d is NGF 30ng / ㎖ Figure 2e is a microscopic observation of the morphological changes of neuronal axons of cells after treatment with NGF 50ng / ㎖ in PC12 cells for 6 days, Figure 2f is a numerical representation of the length of the nerve axons Degrees,

Figure 3a is a diagram showing the effect of nerve axons of PC12 cells by treating only the culture medium as a control, Figure 3b is a crude extract for sarcoma 10㎍ / ㎖, Figure 3c is a ethyl acetate soluble extract for sarcoma, 3d is a nerve After growth of 50 ng / ml growth factor to the culture medium and incubated for 6 days, it is a diagram showing the effect of nerve axons of PC12 cells,

Figure 4a is a photo observing the effect on the growth of nerve axons of PC12 cell line by treating only the culture medium, Figure 4b is 10 ㎍ / ㎖ soluble extract of ethyl acetate for breeding, Figure 4c is 50 ng / ㎖ of nerve growth factor (NGF) cells After adding to the culture medium and culturing, the morphological changes of the cells are photographed with a microscope 200 times magnification,

5 is a measure of apoptosis when the ethyl acetate soluble extract for breeding was removed from the culture medium through LDH and MTT experiments, which shows the effect of treating only the culture solution as 100,

FIG. 6 is an electrophoretic photograph confirming that the ethyl acetate soluble extract for breeding is removed from the cell culture solution and the cells are collected to fragment the DNA.

Figure 7a is a diagram showing the cells cultured by treatment with 50ng / ㎖ NGF, Figure 7b is a diagram showing the cells cultured after the treatment of 50ng / ㎖ nerve growth factor, Figure 7c is for breeding When the cells were removed after treatment with 10 ㎍ / ㎖ ethyl acetate soluble extract, each cell death was shown through fluorescence-activated cell analysis. FIG. 7D is a diagram illustrating ethyl growth factor removal, that is, cell death after induction of cell death. After treatment with 10 ㎍ / ㎖ acetate soluble incubation and analysis,

Figure 8a is an electrophoresis picture showing the gene expression of NGF, Figure 8b is a diagram quantified and quantified,

Figure 9a is a diagram showing the effect on the expression level of NGF receptor by treating only the culture medium using immunocytochemical staining method, Figure 9b is 50 ng / ㎖ of nerve growth factor (NGF), Figure 9c is 10 ㎍ of ethyl acetate soluble extract for breeding / Ml shows the expression level of NGF receptor after treatment

10 is a thin layer chromatography (TLC) photograph of the extract for breeding, which is a sample,

FIG. 11 is a diagram illustrating passive cognitive function increase using saline and sarcoma ethyl acetate extract in mice treated with scopolamine (scopolamine).

In accordance with the above object, the present invention provides crude extracts, polar solvents and non-polar solvent soluble extracts for breeding ( Cistanche deserticola Y.C.MA) effective in the prevention and treatment of degenerative brain diseases.

The present invention also provides a composition for the prevention and treatment of degenerative brain diseases, including crude extract for breeding.

The crude extract means an extract available in a polar solvent selected from water, methanol, butanol or a mixed solvent thereof.

In addition, the present invention provides an extract for preventing and treating degenerative brain disease, including a soluble extract of a polar solvent or a non-polar solvent for breeding.

The polar solvent soluble extract is a solvent selected from water, methanol, butanol or a mixed solvent thereof, preferably an extract soluble in butanol, and the nonpolar solvent soluble extract is a nonpolar solvent such as ethyl acetate and hexane, preferably ethyl acetate. Means an extract soluble in a solvent selected from.

The method for separating crude extract, polar solvent and nonpolar solvent soluble extract from the breeding of the present invention is as follows.

Hereinafter, the present invention will be described in detail.

The extract for breeding of the present invention is about 5 to 20 times, preferably about 10 to 15 times, water, lower alcohol or about 1: 0.1 to 1:10, preferably 1, the weight of the dried breeding weight (kg). These mixed solvents having a mixing ratio (kg / L) of 0.2 to 1: 5 are extracted by an ultrasonic extraction method for about 1 hour to 1 day at an extraction temperature of 10 to 50 ° C, preferably 20 to 30 ° C. Crude extract which is a soluble extract according to water, lower alcohol or a mixed solvent thereof may be obtained by extraction, concentration under reduced pressure and lyophilization.

The present invention provides a composition for the prevention and treatment of degenerative brain diseases, including crude extracts obtained in the extraction process.

In addition, the polar solvent and the non-polar solvent soluble extract purified from the active ingredient of the present invention is suspended after the crude extract in water, it is added to the non-polar solvent of about 1 to 100 times, preferably about 1 to 5 times the volume of the aqueous layer And a non-polar solvent soluble layer can be obtained by fractionation once to 10 times, preferably 2 to 5 times, and may also be carried out in a conventional fractionation process (Harborne JB Phytochemical methods: A guide to modern techniques of plant analysis . 3rd Ed. pp 6-7, 1998).

Hereinafter, the separation process of the polar solvent and the non-polar solvent soluble extract for breeding,

For example, a first step of pulverizing the breeding and ultrasonically extracted with a polar solvent such as water, methanol or butanol and then filtered, concentrated under reduced pressure and lyophilized to obtain a crude extract soluble in a polar solvent;

A second step of suspending the crude extract in water to sequentially dissolve it in a nonpolar solvent such as chloroform and ethyl acetate, and then fractionating and filtering with a separatory funnel to obtain an ethyl acetate soluble extract;

A third step of sequentially fractionating and filtering the aqueous layer using a polar solvent such as butanol, water, etc. to obtain a butanol soluble extract and a water soluble extract;

The ethyl acetate soluble extract, butanol soluble extract and the water soluble extract comprises a separation step consisting of a fourth step of concentrating under reduced pressure to dry.

The present invention provides a crude extract and a non-polar solvent soluble extract obtained by the above-mentioned manufacturing method and effective for treating degenerative brain disease.

The present invention also provides a pharmaceutical composition containing the extract as an active ingredient and effective in preventing and treating degenerative brain diseases.

The degenerative brain disease prevention and treatment composition of the present invention, the crude extract and the non-polar solvent soluble extract based on the total weight of the composition in 0.1 to 20% by weight.

In the above, degenerative brain disease refers to a composition for treating neurological diseases, which is stroke, Parkinson's, senile dementia or Alzheimer's.

Compositions comprising the extract for breeding of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

Compositions comprising extracts according to the invention are formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. Carriers, excipients and diluents which may be used in combination with the extract, and which may be included in the composition comprising the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin , Calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose or lactose and gelatin. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The amount of the extract of the present invention may vary depending on the age, sex, and weight of the patient, but in general, an amount of 5 to 500 mg / kg, preferably 100 to 250 mg / kg, is divided once to three times daily. can do. In addition, the dosage of the extract can be increased or decreased depending on the route of administration, the degree of disease, sex, weight, age and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.

The present invention provides a dietary supplement comprising a crude extract for breeding and a foodstuff acceptable food supplement additive exhibiting a prophylactic effect of degenerative brain disease.

In addition, the present invention provides a dietary supplement comprising a polar solvent or non-polar solvent soluble extract for breeding and a food acceptable food additive which exhibits a prophylactic effect of degenerative brain disease.

Compositions comprising the extracts of the present invention can be used in a variety of drugs, food and beverages for the prevention of degenerative brain diseases. Examples of the food to which the crude extract for the breeding, the polar solvent and the non-polar solvent soluble extract can be added include various foods, beverages, gums, teas, vitamin complexes, health supplements, and the like, and powders, granules and tablets. , Capsules or beverages.

Sarcoma crude extract, polar solvent and non-polar solvent soluble extract itself of the present invention is a drug that can be used with confidence even for long-term use for the purpose of prevention because there is little toxicity and side effects.

The extract of the present invention may be added to food or beverages for the purpose of preventing degenerative brain diseases. At this time, the amount of the extract in the food or beverage is generally added to the health food composition of the present invention 0.01 to 15% by weight of the total food weight, the health beverage composition is 0.02 to 10 g, preferably based on 100 ml Can be added in a ratio of 0.3 to 1 g.

The health beverage composition of the present invention has no particular limitation on the liquid component except for containing the extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Examples of the above-mentioned natural carbohydrates are monosaccharides, for example, disaccharides such as glucose, fructose and the like, for example, maltose, sucrose and the like, and polysaccharides such as dextrin, cyclodextrin and the like. Sugars and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

The present invention is described in more detail based on the following examples, although the present invention is not limited thereto.

Example 1. Preparation of crude extract for breeding

After selecting and cutting 8kg of dry breeding (Jeongsan Cultivate), certified by the Department of Herbal Medicine, College of Oriental Medicine, Kyung Hee University, put 1kg in 3000ml beaker and put 1500ml of 85% methanol (water: methanol = 15:85). After cooling for one day, ultrasonic extraction (Branson, USA) for 1 hour and the supernatant was filtered with filter paper (Whatman) to remove the residue for breeding. The ultrasonic extraction was repeated one more time, and the extract obtained as a whole was filtered through a filter paper and concentrated under reduced pressure. Extracted twice for breeding was soaked in 85% methanol for one more day, and then ultrasonically extracted and concentrated under reduced pressure. The remaining 7 kg was also carried out by the above method, using a freeze dryer (Speed Spec 3000, BioRad, USA). The same dry powder 3.7 kg was obtained and used as a sample.

For breeding used in experiments drug Herbal medicine Scientific name yield(%) Breeding Cistanche herba Cistanche deserticola 45.5%

Example 2 Preparation of Polar Solvents and Nonpolar Solvent Soluble Extracts for Breeding

500 g of the dry extract for breeding in Example 1 was suspended in 300 ml of water, and then, 3 liters of ethyl acetate was added to the separatory funnel, which was partitioned into an ethyl acetate insoluble layer (lower layer) and an ethyl acetate soluble layer (upper layer) to make ethyl acetate soluble. Wealth was collected. The same volume of ethyl acetate solvent as the lower layer (water layer) was repeated five times in the same manner as described above to obtain a substance that can be dissolved in the ethyl acetate layer as much as possible until the color of the solution became light, and then lyophilized to dry. Soluble extract of a nonpolar solvent for breeding was obtained to obtain 8.2 g of ethyl acetate extract for breeding, and the sample was used as a sample. 26 g was obtained and used as a sample of the polar solvent soluble extract for breeding.

Reference Example 1. Preparation of sample for breeding

Crude crude extract and ethyl acetate soluble extract of Examples 1 and 2 were dissolved in PBS (Phosphate buffered saline, pH 7.2) buffer solution, respectively, to a final concentration of 1.0 mg / ml, followed by a membrane using a disposable syringe. It was prepared aseptically using filter paper (0.2 μm, millipore). When the sample was not completely dissolved in PBS buffer solution, it was dissolved in dimethyl sulfoxide (DMSO, dimethyl sulforoxide, Sigma, USA) to adjust the final concentration of DMSO to 0.1% or less and prepared by aseptic operation.

Reference Example 2. Cell Line Culture

After treating PC12 cell line to 3 × 10 ⁴ in a culture vessel (TPP, Switserland) having a diameter of 100 mm, 2.0 g / L sodium hydrogencarbonate (NaHCO _3, sodium bicarbonate), 5% horse serum (HS), Incubated with RPMI 1640 medium (Gibco BRL, USA) containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin antibiotic (10000 U / mL). Heat was inactivated for 30 minutes at, and the cells were cultured while maintaining a 70% humidity and 37 ℃ temperature while continuously supplying a mixture of air (95%) and carbon dioxide (5%). The medium was changed four times a week for 10 ml each and passaged three to four times a week.

Reference Example 3. Treatment of Breeding Samples

Cells attached to a 100 mm culture vessel at a concentration of 1 × 10 ⁷ cells / well were treated with 500 μl of 0.25% Trypsin-EDTA (Gibco BRL, USA) solution to separate the cells from the culture vessel, and then Trypsin-EDTA solution was neutralized with mL of fresh medium and cell suspension was prepared. 10 μl of 0.4% Trypan blue dissolved in PBS buffer solution was added to 20 μl of the cell suspension, and the number of living cells was counted using a cell counter. Poly-D-lysine (Poly-D-lysine, Sigma Co., Ltd.) was diluted to 50 ㎍ / ml PBS buffer solution, and then 2 ml of each well was added to a 6 well cell culture dish and left at 37 ° C for at least 1 hour. It was. After 1 hour, washed with PBS buffer (pH 7.2) and then dried 6-well cell culture dish was used, the cells were diluted to a concentration of 1 × 10 ⁵ cells / well, inoculated in a culture vessel and incubated. After 24 hours of inoculation, the crude extract for breeding of Example 1 was treated with a final concentration of 10 ㎍ / ml and nerve growth factor (NGF) at 50 ng / ml, respectively, and mixed air of 5% carbon dioxide and 95% oxygen. Observed while incubating for 6 days in an incubator in which temperature and humidity were kept under constant and replaced with fresh medium every two days.

Experimental Example 1. Physiological activity assay of crude extract for breeding

In order to assay the physiological activity of the sarcoma crude extract, 10 µg / ml of the crude sarcoma extract of Example 1 was treated with PC12 cells (Bank of Cell Line, Seoul National University Cancer Center). After 6 days, neuronal outgrowth occurred in most cells to differentiate into neuronal like cells (see FIGS. 1A, 1B, 3, 4A, 4B, 4C, and 4D). NGF was treated by concentration to determine the most effective concentration, was used as a control to determine whether the nerve axons enhanced.

After treating crude extracts and ethyl acetate soluble extracts for breeding on PC12 cells, the results showed that the nerve axon growth effect was increased, and the ethyl acetate soluble extracts for sarcoma showed the highest growth (Fig. 3, Fig. 4A, Fig. 3). 4b, 4c, 4d).

Experimental Example 2. Measurement of nerve axon growth by fractions for breeding

Twenty four hours after the sample was treated in Reference Example 3, fresh medium with 50 ng / ml NGF, 1% fetal bovine serum (FBS) and 2% horse serum (HS) was added. After 24 hours, the nerve axons extending from the cell bodies were observed using a phase contrast microscope (CK-25, Olympus, USA) at a constant time every day, and the length was measured on the photograph after the micrograph was taken. If the nerve axons are not visible, it is set to 0, and if it is the same length as the cell core, it is set to 2 if it grows to 2 times the diameter of the cell core, and if it is longer, it is digitized to 3 (Figs. Reference). At this time, the control group was compared with the group treated with 50 ng / ml of the nerve growth factor, and the measured value was the mean ± standard deviation. The data value for each group was analyzed by Student's t-test comparing the control group and each sample group ( ** p <0.01; see FIG. 3 and Table 2). Each extract was treated to 10 μg / ml in the PC12 cell line, and the measurement of nerve axons was shown as a control-to-ratio, and the control group was treated with 50 ng / ml of NGF. The -mark indicates no effect and the breeding showed better neuroaxons growth than the control group (* p <0.01).

Effect of Sarcoma Extract on Neural Axon Growth of PC12 Cells sample Percentage of nerve axons (% of control) Control 100% NGF 133 ± 0.21 Breeding crude extract 132 ± 0.27%

Experimental Example 3. Natural cell death assay for sarcoma

Cells treated with ethyl acetate soluble extract for breeding and nerve growth factor (NGF) were microscopically observed at a certain time every day, and treated with NGF and ethanol soluble extract for breeding under fetal bovine serum depletion medium. After the change of cells was observed. After culturing for 6 days, the cells were replaced with fresh medium to remove NGF and extracts for each sarcoma, and after 24 hours, the morphological changes of the cells and the associated apoptosis were observed. As a result, it was confirmed that the fragmentation of deoxynucleotide (DNA), which is an indicator of apoptosis, occurred in fetal bovine serum depletion medium, and this confirmed that apoptosis was occurring.

Experimental Example 4 LDH Assay for Breeding

To investigate the degree of apoptosis for sarcoma, LDH (lactate dehydrogenase) enzyme inhibitory effect was tested.

After culturing the cells in the absence of nerve growth factors and measuring the free LDH as a culture medium, the soluble ethyl acetate soluble extract was treated with PC12 cells for 6 days, and then 30 μl of the medium was transferred to a 96 well culture dish. In the experimental group, the ethyl acetate soluble extract sample for breeding was treated and incubated for 6 days, then replaced with a fresh medium, and 30 µl of the cultured supernatant was added to a 96-well culture dish for 24 hours. To carry out the LDH assay, 30 µl of a solution of 1.0 mg of NADH dissolved in 1 ml of 0.75 sodium pyruvate was added to a 96-well culture dish, followed by reaction for 30 minutes in a 37 ° C incubator, followed by addition of 30 µl of a color reagent. And further reacted at 37 ° C. for 20 minutes. 100 µl of 0.4 N sodium hydroxide was added to the reaction mixture to stop the reaction. After 5 minutes, the UV absorbance was measured at a wavelength of 405 nm.

As a result, in the group from which the ethyl acetate soluble extract for breeding was removed, it was found that the amount of LDH decreased due to cell death (see FIG. 5).

Experimental Example 5. MTT assay for breeding

In order to determine the degree of natural apoptosis for sarcoma as in Experimental Example 3 by MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide thiazolyl blue) test method Measured.

In order to measure cell viability in the absence of nerve growth factor (NGF), PC12 cells were inoculated at a concentration of 2 × 10 ⁴ cells / well in a 96 well culture dish, and after culturing for 24 hours, ethyl acetate soluble extract for treatment was treated. After 2 days, the medium was removed, and 150 μl of MTT (Sigma) was dissolved in the medium to a final concentration of 0.05 mg / ml. The reaction was carried out for 4 hours in a 37 ° C. incubator. After 4 hours MTT was removed and crystals were dissolved by adding 150 μl of DMSO to each well. Cell viability was measured by measuring UV absorbance at a wavelength of 570 nm using a microplate reader, or ELISA reader (Molecular devices, USA).

As a result, it was confirmed that the survival rate was reduced in the group removed after treating the ethyl acetate soluble extract for breeding, and finally, the cell apoptosis was remarkably enhanced in the cells in which the ethyl acetate soluble extract for breeding was removed (see FIG. 5).

Experimental Example 6 Assay for Apoptosis of Cells for Sarcoma

When the ethyl acetate soluble extract for breeding was removed, deoxynucleotide fragmentation was performed to determine whether apoptosis occurred.

When apoptosis occurs, DNA fragmentation occurs, so that the DNA fragmentation was confirmed using Willie and Morris method in order to confirm the molecular biological induction of apoptosis. Cells were diluted to a concentration of 2.5-5 × 10 ⁶ cells / well, inoculated in a 100 mm cell culture vessel and incubated for 24 hours. After removing the medium and washing with PBS buffer, 10 ml of each medium was added. After shaking the culture vessel treated with a certain concentration of sample, the culture vessel was incubated for 6 days in an incubator mixed with 5% carbon dioxide and 95% oxygen maintained at 37 ° C, and replaced with fresh medium treated with a sample every two days. . 1 ml of 0.25% trypsin-EDTA was added to separate the cells, mixed with the collected cell solution, and centrifuged at 1000 rpm for 5 minutes to remove the supernatant. 500 μl of lysis buffer (5 mmol / L Tris-HCl, pH 7.4), 5 mmol / L EDTA, 0.5% Triton X-100) was added to the cell precipitate and resuspended, followed by a 1.5 mL tube. After 15 minutes and centrifuged at 12,000 rpm for 20 minutes, the supernatant was transferred to a new tube, 1.0 μl of RNA degrading enzyme (RNase) was added to the supernatant, and incubated at 37 ° C. for 1 hour. Subsequently, 1 μl of proteinase was added, and SDS (bio-rad) was added to a final concentration of 1%, followed by incubation at 50 ° C. for 2 hours, and the same amount of phenol-chloroform was mixed for 15 seconds and then mixed at 12,000 rpm. Centrifuge for 10 minutes at and transfer supernatant to a new tube. Add 1/10 volume of 3M sodium acetate, add 2 volumes of ethanol and allow to stand at room temperature for 30 minutes, centrifuge at 12,000 rpm, 4 ° C for 10 minutes, remove supernatant and dry completely. 20 μl TAE buffer was added to dissolve the precipitate. In order to identify the fragments of the isolated DNA, agarose gel (Gibco BRL, USA) was prepared using 1 × TAE buffer solution and subjected to electrophoresis. 10 μl of the isolated DNA was mixed with the staining agent, followed by electrophoresis at 100 volts for 40 minutes, and fragmentation using an electrophoretic gel Gel-DOC (gel doc 2000, Bio-Rad, USA). Was measured.

As a result, in Fig. 6a, 1 was treated with 50 ng / ml of NGF, 2 was treated with 10 ㎍ / ml of crude extract for breeding, and 3 was treated with 10 ㎍ / ml of ethyl acetate soluble extract for breeding. One, 4 is fetal calf serum removed, cells removed after treatment of crude extracts and ethyl acetate soluble extracts for breeding, DNA fragmentation occurred can be seen apoptosis (see Figure 6a), cell nature After removal of fetal bovine serum reported to kill, 1 of FIG. 6B treated 50 ng / ml of NGF, 2 treated with 10 µg / ml of crude extract for breeding, and 3 showed ethyl for breeding. Treated with 10 μg / ml of the acetate soluble extract, 4 was the addition of fetal bovine serum, and the DNA fragmentation did not occur when the crude extract for breeding and the ethyl acetate soluble extract were treated (see FIG. 6B).

As a result, fragmentation was observed in the group from which the crude extract and ethyl acetate soluble extract were removed, and DNA fragmentation did not occur when the crude extract and ethyl acetate soluble extract were treated after fetal calf serum removal. As such, it was confirmed that crude extract and ethyl acetate soluble extract for breeding inhibited apoptosis.

Experimental Example 7 Analysis of Fluorescent Active Cells for Sarcoma

To quantify the effects of sarcoma on apoptosis, the cells were analyzed using a fluorescent activated cell collector (FACS).

After 24 hours of incubation of PC12 cells in complete medium, the cells were replaced with serum depleted medium containing 2% horse serum and 1% fetal bovine serum, and the growth factor (NGF) and ethyl acetate soluble extract for breeding were changed. Were treated respectively. After 24 hours of incubation, the suspension containing the suspension was centrifuged at 200 g for 5 minutes, and 100 μl of the fluorescent material was removed from the supernatant as an annexin V-FITC (Biorad, USA). This was added to a buffer solution, 10 mM HEPES pH 7.4, 150 mM sodium chloride, 5 mM potassium chloride, 1 mM magnesium chloride, 1.8 mM calcium chloride, dissolved, and wrapped in foil for 5 minutes at room temperature. After placing the HEPES buffer in the FACS small tube, 20 µl of propidium iodide (PI) (100 µg / ml in HEPES buffer) was added and analyzed.

PI is a kind of DNA binding dye that allows measuring the amount or binding of DNA to each cell. When apoptosis occurs, PI binds to DNA.

As a result, FACS analysis was performed to quantify the induction of apoptosis. When apoptosis occurs, cells move to the lower left part of the graph. That is, when the ethyl acetate soluble extract for breeding is removed from the culture solution, it can be seen that apoptosis occurs, and the number of cells moves to the lower right side as time passes. The lower left represents living viable cells, the lower right represents apoptosis, and the upper right represents necrosis. This resulted in apoptosis after 4 hours of removal of ethyl acetate fraction and neuronal growth factor (NGF) for sarcoma, and most frequent after 12 hours, and cell death was induced after 12 hours. (See Figures 7A, 7B 7C, 7D).

Experimental Example 8. Screening of Apoptosis Defense for Sarcoma

In order to detect the defense against apoptosis for sarcoma, PC12 cells were cultured in a complete medium and then replaced with a medium without serum and neural growth factor, and cell apoptosis was induced by incubating the cells for 24 hours. In order to determine whether the ethyl acetate fraction for sarcoma protects against death of PC12 cells induced by serum depletion, it was cultured in serum-free medium for 12 hours, and then treated with ethyl acetate soluble extract for sarcoma to observe the morphological changes of cells over time. DNA was isolated to identify fragments, and FACS analysis confirmed apoptosis inhibition (FIGS. 7A, 7B, 7C, and 7D).

Experimental Example 9. Gene Expression of Neural Growth Factor (NGF)

Gene Expression Identification Using Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)

Ribonucleotides (RNA) of whole cells were isolated using Trizol B solution (Gibco BRL). After lysing the cells by treating 1 ml of Trizol B solution, 1.5 ml of the cell lysate obtained using the cell collector was transferred to a small tube and homogenized with a 21G syringe. The cell lysate was centrifuged at 12,000 rpm for 10 minutes at 4 ° C., and then the same amount of chloroform was added to the supernatant, followed by being left at room temperature for 15 minutes, followed by centrifugation at 4 ° C. and 12,000 rpm for 15 minutes. Only the supernatant, ie, RNA layer, was taken and transferred to a new small tube. The same amount of 100% isopropanol was mixed and left at room temperature for 15 minutes, followed by centrifugation at 4 ° C and 12,000 rpm for 15 minutes. After removing the supernatant, 1.0 ml of 75% ethanol was added to the obtained ribonucleotide precipitate, and the resultant was centrifuged at 12,000 rpm for 5 minutes at 4 ° C. After completely drying at room temperature for 10 minutes, the precipitate was dissolved in 100 μl of DEPC (diethylpyrocabonate) -treated distilled water, and measured at UV 260 nm and 240 nm using an absorbance meter (Bio-Rad, USA).

Complementary deoxynucleotide (cDNA) synthesis was performed using reverse transcriptase and polymerase chain reaction was performed using Taq polymerase (TaKaRa, Japan). 1 μg of the extracted RNA was isolated by treatment at 65 ° C. for 15 minutes, followed by reaction solution (4 μl 5 × buffer, 1 μl 10 mM dNTP (deoxy nucleotide) mixture, 1 μl 20 μM oligo ( dT) ₁₅ primer, 0.2 μl 200 U / μl M-mlV Reverse transcriptase, 2 μl 0.1 M dithiothreitol, made up of 20 μl final volume with DEPC treated distilled water), Complementary deoxynucleotide (cDNA) was synthesized by reacting at 37 ° C. for 60 minutes and 72 ° C. for 15 minutes. 1 μl cDNA synthesized on the polymerase chain reaction reaction solution (10 × buffer solution 2.5 μl, 2.5 mM dNTP mixture 2 μl, 5 U / μl Taq polymerase 0.2 μl, 10 μM sense primer 1 μl, 10 μM antisense primer 1 μl , DEPC treated with distilled water to prepare a final volume of 25 μl) was reacted in a polymerization chain reaction machine (Perkin Elmer, USA) under the conditions of Table 3 below. The nerve growth factor (NGF) PCT product is 860 bp, the sense primer is described in SEQ ID NO: 1, the antisense primer is described in SEQ ID NO: 2, the GAPDH PCR product is 307 bp, the sense primer is located in SEQ ID NO: 3, Antisense primers are described.

Polymerization Chain Reaction Table 95 ℃ 3 minutes 1 time denaturalization 95 ℃ 30 seconds 30 times Combination 62 ℃ 30 seconds kidney 72 ℃ 1 minute 72 ℃ 7 minutes 1 time

10 μl of reverse transcriptase (RT-PCR product) was analyzed by electrophoresis on 1.5% agarose gel (Gibco BRL, USA). Electrophoresis was performed for 30 minutes at a voltage of 100 volts, 1 × TAE buffer solution was used, agarose gel was stained with ethidium bromide solution for 20 minutes, and then again in distilled water 10 After destaining for a minute, and irradiated with ultraviolet light to observe the results of electrophoresis, gel-DOC was used to photograph (see Fig. 8a), it was numerically represented as a graph (see Fig. 8b).

As a comparative gene, GAPDH having a size of 250 base pairs was used. Based on this, only culture medium, 50 ng / ml of nerve growth factor, 10 ㎍ / ml of crude extract for breeding, and ethyl acetate soluble extract for breeding 10 In comparison with the treatment of ㎍ / ㎖, it was possible to compare the expression level of nerve growth factor genes, and it was confirmed that crude extracts and ethyl acetate soluble extracts for breeding increased neuronal growth factor (NGF) receptor expression levels.

Gene Expression Identification Using Immunocytochemistry

The effects of sarcoma crude extract and nonpolar solvent soluble extract on the expression level of p75 receptor, NGF receptor, were examined by immunocytochemistry.

PC12 cells were cultured on glass coverslips (22 mm x 22 mm) in complete medium, and after 24 hours, 10 μl / ml of ethyl acetate soluble extract for breeding and 50 ng / ml of neuronal growth factor (NGF) were treated. It was. After 48 hours, the cells were fixed for 30 minutes at room temperature with 2% fixative paraformaldehyde (Phosphate buffer pH 7.4) and washed with PBS buffer, followed by 2% BSA (Bovine serum albumin) and 0.1% Triton X-100 solution. The reaction was carried out on ice for 30 minutes to remove nonspecific reactions and to increase the permeability of cell membranes. The mixture was washed three times for 10 minutes with PBS buffer and 1% BSA mixed solution, and the primary antibody anti-p75 (1: 2000 dilution, LSA Labs) was reacted with PBS buffer for 1 hour. Again washed three times with PBS buffer and 1% BSA mixture and then 1 hour with secondary antibody anti-mouse immunoglobulin G (Anti-mouse IgG, Weed Lab Co., Ltd. (1: 5000 dilution) After the reaction, the cells were washed and observed by fluorescence microscopy.

As a result, it was confirmed that the expression level of p75 receptor was increased in the NGF-added group and the ethyl acetate soluble extract treated group for breeding than the control group. That is, it was confirmed that the protein expression of p75, a neuronal growth factor (NGF) receptor, was increased in cells treated with 10 μg / ml ethyl acetate soluble extract for breeding (see FIGS. 9A, 9B, and 9C).

It can be assumed that the ethyl acetate soluble extract for sarcoma increases the expression of receptors by increasing the synthesis of nerve growth factor (NGF), which induces the growth and differentiation of PC12 cells. In addition, the ethyl acetate soluble extract for sarcoma promoted the expression of nerve growth factor (NGF) by directly interacting with the receptor.

As a result, it was found that the expression level of NGF gene was increased in the group treated with the ethyl acetate soluble extract for breeding (see FIGS. 9A, 9B, and 9C), indicating that the ethyl acetate soluble extract for breeding increased the synthesis of NGF in the cells. You can see.

Experimental Example 10. Toxicity test for breeding

Animal experiments were carried out to confirm the toxicity of the crude extracts and ethyl acetate soluble extracts of Example 1 and Example 2.

Oral administration

ICR-based mice (central laboratory animals) and five-week-old Sprague Dawley (SD) -based males of about 250 to 300 g each were divided into four groups of 10 males, and then the extract for breeding of the present invention (methanol extract for breeding, for breeding) Butanol extract, ethyl acetate soluble extract for breeding, water extract for breeding) were orally administered at doses of 500, 725, 1000 and 5000 mg / kg, respectively. After oral administration, toxicity was observed for two weeks, and none of the four groups died. No apparent symptoms were found.

Intraperitoneal administration

ICR-based mice (central laboratory animals) and five-week-old Sprague Dawley (SD) -based males of about 250 to 300 g each divided into four groups of 10 males and then the breeding extract of the present invention (methanol extract for breeding, Sarcoma butanol extract, sarcoma ethyl acetate extract, and sarcoma water extract) were intraperitoneally administered at doses of 25, 250, 500 and 725 mg / kg, respectively. Marie also did not die and apparently found no symptoms.

Passive avoidance test

Sarcoma ethyl acetate extract was administered 1 hour before inducing dementia to determine the effect on passive learning ability.

ICR mice (25-30g, male) were placed in a box divided into two rooms (avoidance shuttle box, 40 X 20 X 20 cm, Gemini, USA) with a grid of 3 mm thick at the bottom. Put in one room to lighten.

Once a mouse who prefers a dark place enters the other dark room from the bright room, a training session was performed to receive electric stimulation (0.1 mA / 10 g body weight) through a grid installed at the bottom. Minus (scopolamine) was administered to the mice 30 minutes before training to induce brain lesions. After 24 hours, the same experiment was conducted to measure the time the mice stayed in the bright room, which was used as an index to remember the previous day's training through electric stimulation.

As a result, when scopolamine was used to induce memory impairment, the mice stayed in the brightest room for the shortest time. Mice treated with saline as a control showed a normal response, whereas the induction of memory impairment was induced. The mice treated with the ethyl acetate extract for breeding later increased the time to stay in the bright room. That is, it was found that the cognitive function of the mouse was improved, and the effect of increasing the passive cognitive function was confirmed by increasing the expression level of nerve growth factor in the animal (see FIG. 11).

The extract for breeding of the present invention can be administered in the following formulations, and the following formulation examples are merely to illustrate the invention, whereby the content of the invention is not limited.

Formulation Example 1 Preparation of Injection

Crude extract for breeding of Example 1 100 mg

Sodium Metabisulfite3.0 mg

Methylparaben0.8 mg

Propylparaben0.1 mg

Sterile Distillation Amount for Injection

The above ingredients are mixed and prepared in a conventional manner to have a final volume of 2 ml, and then filled into 2 ml ampoules and sterilized to prepare an injection.

Formulation Example 2 Preparation of Tablet

200 mg ethyl acetate extract for broth of Example 2

Lactose 100 mg

Starch 100 mg

Magnesium stearate proper amount

A tablet is prepared by mixing and tableting the above components according to a conventional tablet manufacturing method.

Formulation Example 3 Preparation of Capsule

Crude extract for breeding of Example 1 100 mg

Lactose 50 mg

Starch 50 mg

Talc 2 mg

Magnesium stearate

According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

Formulation Example 4 Preparation of Liquid

1000 mg of butanol extract for breeding of Example 2

20 g of sugar

Isomerized sugar 20 g

Lemon flavor

Purified water was added to make a total of 1000 ml. According to the conventional method for preparing a liquid, the above components are mixed, and then filled into a brown bottle and sterilized to prepare a liquid.

Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, use purpose.

Preparation Example 5 Preparation of Mixed Liquid

1000 mg of crude extract for breeding in Example 1

Rapid extract 1000mg

Citric Acid1000 mg

Oligosaccharides 100 g

Plum concentrate 2 g

1 g of taurine

Lemon flavor

Add 100 ml of purified water

According to the conventional method for preparing a liquid, the above components are mixed, and then filled into a brown bottle and sterilized to prepare a liquid. The fast extract and Guchu extract can be prepared in the same manner as Guchu extract of the present invention.

Formulation Example 6 Preparation of Healthy Food

1000 mg of crude extract for breeding in Example 1

Vitamin mixture

Vitamin A Acetate70 μg

Vitamin E1.0 mg

Vitamin B ₁ 0.13 mg

Vitamin B ₂ 0.15 mg

Vitamin B ₆ 0.5 mg

0.2 μg of vitamin B ₁₂

Vitamin C10 mg

Biotin 10 ㎍

Nicotinic Acid Amide1.7 mg

Folic acid 50 ㎍

Calcium Pantothenate 0.5 mg

Mineral mixture

Ferrous Sulfate1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate25.3 mg

Potassium phosphate monobasic 15 mg

Dibasic calcium phosphate55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.

Formulation Example 7 Preparation of Healthy Drink

1000 mg of crude extract for breeding in Example 1

Citric Acid1000 mg

Oligosaccharides 100 g

Plum concentrate 2 g

1 g of taurine

Add 900 ml of purified water

After mixing the above components in accordance with a conventional healthy beverage production method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions.

Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, use purpose.

Sarcoma extract of the present invention induces the growth and differentiation of neurons, and exhibits the effect of maintaining survival, can replace the role of neuronal axon growth and neuronal growth factor that plays an important role in degenerative brain disease In addition, it can be used as a medicine and health supplement food composed of non-toxic natural medicine.

Claims (17)

Crude extract of Cistanche deserticola Y.C.MA, which shows the prophylactic and therapeutic effect of degenerative brain disease. The extract of claim 1 wherein the crude extract is soluble in a polar solvent selected from water, methanol, butanol or a mixed solvent thereof. Soluble extract of polar solvent for breeding, showing the effect of preventing and treating degenerative brain diseases. The extract of claim 3 wherein the polar solvent is soluble in a solvent selected from water, methanol, butanol or a mixed solvent thereof. Soluble extract of nonpolar solvent for sarcoma showing prevention and treatment effect of degenerative brain disease. The extract of claim 5, wherein the nonpolar solvent is soluble in a solvent selected from hexane, chloroform, ethyl acetate. Pharmaceutical composition for the prevention of degenerative brain diseases, including crude extract for breeding as an active ingredient. Pharmaceutical composition for the prevention of degenerative brain disease, comprising as an active ingredient a polar solvent soluble extract for breeding. Pharmaceutical composition for the prevention of degenerative brain disease, comprising a non-polar solvent soluble extract for breeding as an active ingredient. The pharmaceutical composition according to any one of claims 7 to 9, comprising 0.1 to 20% by weight of the extract. The composition of claim 7, wherein the degenerative brain disease is stroke, Parkinson's, senile dementia or Alzheimer's disease. The composition for treating degenerative brain disease according to any one of claims 7 to 9, wherein the composition is a tablet, a capsule, a solution, a suspension, or a syrup. The pharmaceutical composition according to any one of claims 7 to 9, wherein the daily dosage of the composition is from 5 mg to 500 mg per kg of body weight. A dietary supplement comprising a crude extract for breeding and a food-acceptable food supplement additive that has a preventive effect on degenerative brain disease. A dietary supplement comprising a polar solvent-soluble extract for food breeding and a food supplement acceptable food additive that exhibit a prophylactic effect of degenerative brain disease. A dietary supplement comprising a non-polar solvent soluble extract for breeding and a food acceptable acceptable food supplement, which exhibits a prophylactic effect of degenerative brain disease. The dietary supplement according to any one of claims 14 to 16, which is a powder, granule, tablet, capsule or beverage.